Of 15 guidance figures from CVS HEALTH's earnings releases that Stock Atlas has scored against the reported result, 12 came in above the guide, 1 in range and 2 below. It met or beat its own guidance 87% of the time.
| Period | Measure | Guided | Reported | Result |
|---|---|---|---|---|
| FY2025 | Operating Income | $4.37B to $4.54B | $4.66B | above |
| FY2025 | Revenue | $400.00B | $402.07B | above |
| FY2025 | Cash Flow From Operations | $7.50B | $10.64B | above |
| FY2024 | Cash Flow From Operations | $9.00B | $9.11B | above |
| FY2024 | Net Income | $6.25B to $6.56B | $4.59B | below |
| FY2024 | Total revenues | $366.00B | $372.81B | above |
| FY2023 | Cash Flow From Operations | $12.50B to $13.50B | $13.43B | in range |
| FY2023 | Total revenues | $351.50B to $357.30B | $357.78B | above |
Above means the reported figure beat the top of the range, in range that it landed inside it or on a point guide, below that it missed. Every guide and revision, and screens across companies, are in the research platform.
Do companies beat their own guidance? The study · Back to CVS HEALTH financials
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “CVS HEALTH (CVS) guidance record”, stockatlas.com/companies/CVS/guidance/, data as of 3 November 2026. Links to this page are welcome.
